TURNING POINT THERAPEUTICS I's ticker is TPTX and the CUSIP is 90041T108. A total of 193 filers reported holding TURNING POINT THERAPEUTICS I in Q2 2021. The put-call ratio across all filers is 1.94 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2022 | $4,333,000 | +190.8% | 57,586 | +3.8% | 0.01% | +250.0% |
| Q1 2022 | $1,490,000 | -48.4% | 55,502 | -8.3% | 0.00% | -33.3% |
| Q4 2021 | $2,886,000 | -26.4% | 60,505 | +2.5% | 0.00% | -40.0% |
| Q3 2021 | $3,922,000 | -20.7% | 59,034 | -6.9% | 0.01% | -16.7% |
| Q2 2021 | $4,945,000 | -7.2% | 63,376 | +12.6% | 0.01% | -14.3% |
| Q1 2021 | $5,326,000 | -22.6% | 56,301 | -0.3% | 0.01% | -30.0% |
| Q4 2020 | $6,881,000 | +52.4% | 56,471 | +9.3% | 0.01% | +42.9% |
| Q3 2020 | $4,514,000 | +65.6% | 51,676 | +22.4% | 0.01% | +40.0% |
| Q2 2020 | $2,726,000 | +45.9% | 42,207 | +0.9% | 0.01% | +25.0% |
| Q1 2020 | $1,868,000 | -29.1% | 41,828 | -1.1% | 0.00% | 0.0% |
| Q4 2019 | $2,635,000 | +586.2% | 42,300 | +313.7% | 0.00% | +300.0% |
| Q3 2019 | $384,000 | -7.7% | 10,225 | 0.0% | 0.00% | 0.0% |
| Q2 2019 | $416,000 | – | 10,225 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Cormorant Asset Management, LP | 2,737,297 | $176,802,000 | 6.75% |
| MPM BioImpact LLC | 308,686 | $19,938,000 | 5.30% |
| Burrage Capital Management LLC | 77,172 | $4,985,000 | 3.49% |
| Orbimed Advisors | 2,745,327 | $177,321,000 | 2.50% |
| Parkman Healthcare Partners LLC | 110,318 | $7,125,000 | 2.01% |
| SECTORAL ASSET MANAGEMENT INC | 284,486 | $18,375,000 | 1.69% |
| First Light Asset Management, LLC | 192,829 | $12,455,000 | 1.45% |
| Asymmetry Capital Management, L.P. | 22,608 | $1,460,000 | 1.12% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 35,000 | $2,236,000 | 0.74% |
| Prosight Management, LP | 25,602 | $1,654,000 | 0.71% |